GRANULES
Granules India Limited (GRANULES) Stock Analysis
Granules India Limited is an Indian pharmaceutical manufacturer focused on APIs, intermediates, and finished dosages. It supplies large-volume oral products and PFIs to global generics customers. The company operates multiple plants in India. It is listed on Indian stock exchanges.
Healthcare › Drug Manufacturers - Specialty & Generic
₹825.40
+1.24% 1W | +42.10% 52W
Market Cap
22.5k CR
P/E Ratio
30.7
52W High
₹923.6
52W Low
₹529.9
Div. Yield
0.22%
Beta
0.1
50 DMA
₹851.3
200 DMA
₹731.5
Profit Margin
11.8%
Inst. Own.
22.3%
✅ BOUNCE FROM SUPPORT
✅ BOUNCE FROM SUPPORT
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 986 | 1,189 | 1,156 | 1,176 | 1,180 | 967 | 1,138 | 1,197 | 1,210 | 1,297 | 1,388 | 1,471 | 1,477 |
| Expenses | 849 | 977 | 905 | 920 | 921 | 763 | 907 | 945 | 963 | 1,019 | 1,080 | 1,119 | 1,138 |
| Operating Profit | 137 | 213 | 250 | 256 | 259 | 203 | 230 | 252 | 247 | 278 | 308 | 352 | 339 |
| OPM % | 14% | 18% | 22% | 22% | 22% | 21% | 20% | 21% | 20% | 21% | 22% | 24% | 23% |
| Other Income | 0 | 2 | 1 | 2 | 2 | 3 | 6 | 33 | -10 | -1 | -4 | 25 | 2 |
| Interest | 22 | 26 | 29 | 29 | 27 | 26 | 27 | 24 | 24 | 29 | 29 | 33 | 21 |
| Depreciation | 49 | 53 | 52 | 53 | 53 | 53 | 57 | 64 | 69 | 72 | 74 | 82 | 80 |
| Profit before tax | 65 | 136 | 170 | 176 | 181 | 128 | 153 | 198 | 145 | 176 | 202 | 262 | 240 |
| Tax % | 27% | 25% | 26% | 26% | 26% | 24% | 23% | 23% | 22% | 26% | 26% | 23% | 25% |
| Net Profit | 48 | 102 | 126 | 130 | 135 | 97 | 118 | 152 | 113 | 131 | 150 | 202 | 180 |
| EPS in Rs | 1.98 | 4.21 | 5.18 | 5.35 | 5.56 | 4.01 | 4.85 | 6.27 | 4.64 | 5.38 | 6.19 | 8.13 | 7.26 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,292 | 1,357 | 1,411 | 1,685 | 2,279 | 2,599 | 3,238 | 3,765 | 4,512 | 4,506 | 4,482 | 5,366 | 5,632 |
| Expenses | 1,082 | 1,081 | 1,112 | 1,406 | 1,895 | 2,073 | 2,382 | 3,038 | 3,597 | 3,648 | 3,534 | 4,177 | 4,355 |
| Operating Profit | 210 | 276 | 299 | 278 | 384 | 526 | 856 | 727 | 915 | 858 | 948 | 1,188 | 1,277 |
| OPM % | 16% | 20% | 21% | 17% | 17% | 20% | 26% | 19% | 20% | 19% | 21% | 22% | 23% |
| Other Income | 3 | 5 | 35 | 27 | 75 | 90 | 26 | 13 | 12 | 2 | 41 | 7 | 22 |
| Interest | 32 | 37 | 32 | 33 | 28 | 27 | 26 | 23 | 56 | 106 | 103 | 114 | 112 |
| Depreciation | 53 | 58 | 72 | 76 | 105 | 137 | 151 | 159 | 184 | 207 | 226 | 296 | 307 |
| Profit before tax | 128 | 186 | 230 | 196 | 326 | 451 | 704 | 558 | 687 | 547 | 660 | 785 | 881 |
| Tax % | 29% | 33% | 28% | 32% | 27% | 26% | 22% | 26% | 25% | 26% | 24% | 24% | |
| Net Profit | 91 | 123 | 165 | 133 | 236 | 335 | 549 | 413 | 517 | 405 | 502 | 595 | 662 |
| EPS in Rs | 4.45 | 5.68 | 7.19 | 5.22 | 9.30 | 13.19 | 22.18 | 16.64 | 21.34 | 16.72 | 20.68 | 24.01 | 26.96 |
| Dividend Payout % | 11% | 11% | 13% | 19% | 11% | 8% | 7% | 9% | 7% | 9% | 7% | 7% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 6.0% | 11.0% | 15.0% |
| Profit CAGR | 5.0% | 2.0% | 17.0% |
Shareholding Pattern
Promoters38.81%
FIIs14.09%
DIIs17.91%
Public29.17%
Promoters38.81%
FIIs13.55%
DIIs17.47%
Public30.15%
Promoters38.02%
FIIs15.31%
DIIs17.01%
Public29.67%
Promoters38.01%
FIIs17.50%
DIIs16.11%
Public28.36%
Promoters37.39%
FIIs20.25%
DIIs15.33%
Public27.04%
Promoters42.02%
FIIs23.90%
DIIs5.03%
Public29.05%
Promoters41.96%
FIIs19.57%
DIIs10.70%
Public27.77%
Promoters38.83%
FIIs15.14%
DIIs22.45%
Public23.56%
Promoters38.02%
FIIs15.31%
DIIs17.01%
Public29.67%
Promoters37.39%
FIIs20.25%
DIIs15.33%
Public27.04%
GRANULES
Holdings Analysis
Key strengths & risk signals
67
Overall
51
Fundamental
84
Technical
Risks (3)
OVERVALUED! PEG of 6.40 means expensive relative to growth rate.
RECOVERY MODE! Current price (825.4) above 200-day but below 50-day.
WEAK MOMENTUM! Limited price growth - 1.2% (1 week), -1.2% (1 month), -6.3% (3 months).
Strengths (4)
MODERATE STABILITY! 2 revenue dips in history. Acceptable but monitor closely.
BULLISH TREND! 50-day average (851.3) is above 200-day average (731.5) - positive signal.
GOOD YEAR! Stock gained 42.1% in the last year.
BULLISH SENTIMENT! In last 30 days: 15 up days, 15 down days. Avg volume on up days: 1,599,110 vs down days: 908,887. Ratio: 1.76x
Fundamental & Technical Analysis
67Overall
51Fundamental
84Technical
Fundamental Breakdown
Growth Quality
13/30
Revenue CAGR: 5.9% (MODERATE, 8/15). Profit CAGR: 4.8% (SLOW, 5/15).
Profit Margin
5/10
DECENT EFFICIENCY! 11.8% profit margin - acceptable profitability.
PEG Valuation
0/10
OVERVALUED! PEG of 6.40 means expensive relative to growth rate.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.22% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
14/20
MODERATE PUBLIC HOLDING! 29.95% public ownership - balanced ownership structure.
Stability Index
6/10
MODERATE STABILITY! 2 revenue dips in history. Acceptable but monitor closely.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (851.3) is above 200-day average (731.5) - positive signal.
Price Position
2/10
RECOVERY MODE! Current price (825.4) above 200-day but below 50-day.
Trend Pattern
16/20
TESTING SUPPORT! Stock is at key support level.
52W Performance
10/10
GOOD YEAR! Stock gained 42.1% in the last year.
Volume Sentiment
30/30
BULLISH SENTIMENT! In last 30 days: 15 up days, 15 down days. Avg volume on up days: 1,599,110 vs down days: 908,887. Ratio: 1.76x
RSI
3/5
NEUTRAL! RSI at 46.5 - balanced momentum.
52W Range
4/5
UPPER HALF! Trading at 75.1% of 52W range - positive territory.
Momentum
2/5
WEAK MOMENTUM! Limited price growth - 1.2% (1 week), -1.2% (1 month), -6.3% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.10 - stable stock, less market risk.
GRANULES
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q1FY272026-10-06 | Concall PDF | |
| Q4FY262026-07-27 | Concall PDF | |
| Q2FY262026-01-28 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GRANULES | ₹825.40 | 30.7 | 11.8% | 5.9% | 4.8% | +42.1% | 67 | BOUNCE FROM SUPPORT | +59.9% | -10.7% | +21.2% | +0.5% |
| NEULANDLAB | ₹19,675.00 | 50.7 | 21.0% | 18.5% | 30.6% | +24.1% | 74 | BREAKDOWN | +962.6% | -30.6% | +119.1% | -17.4% |
| PPLPHARMA | ₹197.70 | – | -3.4% | 7.6% | – | +0.7% | 55 | APPROACHING SUPPORT | -15.1% | +688.6% | +17.4% | -17.5% |
| WOCKPHARMA | ₹1,954.90 | 77.5 | 11.2% | 7.8% | – | +46.4% | 58 | BREAKDOWN | -217.8% | -36.1% | +25.9% | -3.7% |
| EMCURE | ₹1,820.60 | 34.1 | 10.4% | 15.4% | 20.2% | +36.3% | 81 | BREAKDOWN | +42.0% | +20.8% | +22.8% | +4.5% |
| AJANTPHARM | ₹3,329.00 | 36.7 | 19.6% | 13.4% | 21.6% | +37.8% | 82 | BOUNCE FROM SUPPORT | +30.9% | +25.3% | +24.8% | +14.4% |
| IPCALAB | ₹1,832.60 | 35.5 | 12.9% | 15.5% | 34.3% | +48.6% | 78 | BREAKDOWN | +72.3% | +34.4% | +20.8% | +16.7% |
| GLAND | ₹3,043.40 | 44.4 | 16.8% | 21.3% | 9.6% | +59.2% | 83 | BREAKOUT | +47.1% | -13.6% | +19.6% | +3.3% |
Data from TradeAlone · Updated daily
GRANULES News
Granules India Limited (granules) Gains Potential First-to-file Status on Ruxolitinib Extended-release Tablets ANDA2026-10-07Granules India Limited (GRANULES) shows pressure after breakout, falls 5% intraday2026-07-22Granules India Limited (granules) Q1 FY27: Revenue Up 22% Yoy, PAT Surges 60%2026-07-21Granules India Limited (granules) Secures Sole First-to-file ANDA Status for Sodium Oxybate Extended-release for Oral Suspension2026-07-06Granules India Limited (granules): USFDA EIR Received for Chantilly Facility with VAI Classification2026-06-03
